Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

Inclusion Criteria:

• Participants at increased risk for severe RSV infection recommended to receivepalivizumab in accordance with national or local guidelines or professional societyrecommendations.

• Is available to complete the follow-up period.

Exclusion Criteria:

• Requires mechanical ventilation at time of enrollment.

• Has a life expectancy <6 months.

• Has known hepatic or renal dysfunction, or chronic seizure disorder.

• Is hospitalized at the time of randomization unless discharge is expected within 7days after randomization.

• Has severe immunodeficiency or is severely immunocompromised.

• Has known hypersensitivity to any component of clesrovimab or palivizumab.